Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
|
26229107 |
2015 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We examined the association of clinical and pathological characteristics of breast tumors and breast cancer risk factors according to the prevalence and type of p53 mutations.
|
26364297 |
2015 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The association of lymphocytic invasion of ER-negative breast tumors with the retention of wild-type TP53 implies a novel protective connection between TP53 function and tumor immunosurveillance.
|
25351767 |
2015 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Through the described mechanism, elevated CXCR5 expression may contribute to abnormal cell survival and migration in breast tumors that lack functional p53.
|
25786345 |
2015 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These results have translational relevance, demonstrating that TP53 mutant breast tumor growth can be suppressed by pharmacologic TLR4 inhibition, whereas TLR4 inhibitors may in fact promote growth of TP53 wild-type tumors.
|
26063617 |
2015 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We have predicted three deleterious coding non-synonymous single nucleotide polymorphisms rs11540654 (rs11540654" genes_norm="7157">R110P), rs17849781 (rs17849781" genes_norm="7157">P278A) and rs28934874 (rs28934874" genes_norm="7157">P151T) in TP53 with a phenotype in breast tumors using computational tools SIFT, Polyphen-2 and MutDB.
|
25105660 |
2014 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, Notch-induced transcriptomes from p53 wild-type and -mutated breast tumor cell lines differed extensively, and for a subset of genes upregulated by Notch in a p53-mutant cell line, this upregulation was reduced by wild-type p53.
|
23178494 |
2013 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Household income is associated with the p53 mutation frequency in human breast tumors.
|
23469190 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
|
23657012 |
2013 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Through search for other possible p53 E3 ligases by mRNA and protein expression analysis, downregulation of TNF receptor-associated factor 7 (TRAF7) expression was found in these breast tumors.
|
23128672 |
2013 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We investigated the p53 mutation status in 572 breast tumors, classified into luminal, basal and molecular apocrine subgroups.
|
22886769 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
In this study we assessed the effects of the phytocompounds garcinol and curcumin on histone and p53 modification in cancer cells, focussing on the breast tumour cell line MCF7.
|
23356739 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Our results showed that telomeres were significantly shorter in tumors with somatic p53 mutations compared with tumors with wild-type p53 in both breast tumors (P=0.007) and esophageal cancer (P=0.001).
|
23124483 |
2013 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
|
22797073 |
2013 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Deletion of TP53 was the most frequent alteration observed, suggesting that if this alteration is present in the primary tumors, breast tumors with loss of TP53 copies have a poorer prognosis and a higher chance for metastasis.
|
23315874 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
We have previously tested biopsies from 1469 breast tumours with a p53 functional assay in the context of a prospective clinical trial (EORTC 10994/BIG 1-00).
|
23897043 |
2013 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this study, expression of mature miR-34a in breast tumors with wild-type p53 was investigated in order to find any correlation between dysregulation of miR-34a expression and breast cancer.
|
23292869 |
2013 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.
|
23794094 |
2013 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Expression of EXO1 module was found as indicative of elevated cell proliferation, genomic instability, activated RAS/AKT/MYC/E2F1 signaling pathways and loss of p53 activity in breast tumors. mRNA-drug connectivity analysis indicates inhibition of RAS/PI3K as a possible targeted therapeutic approach for the patients with activated EXO1 module in breast tumors.
|
24147022 |
2013 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of the frequency of cells with single or combined alterations.
|
22628410 |
2012 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
These results suggest that specific p53 mutations may contribute to loss of estrogen receptor α expression in breast tumors and also support the hypothesis that mutant p53 is likely to impact DNA methylation.
|
21655924 |
2012 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
|
21683430 |
2012 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The Oncomine database was explored for TrxR1 (TXNRD1) expression in breast tumors and TrxR1, ER and p53 expression was analyzed by immunohistochemistry in a panel of breast tumors.
|
23216744 |
2012 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
|
21512767 |
2012 |